title: R-CHOP therapy alone for limited-stage follicular lymphoma.
abstract: Irradiation therapy alone is a standard strategy for limited-stage FL, leading to a 10-year progression-free survival (PFS) rate of 30-50%. However, we have been administering R-CHOP therapy alone to patients with limited-stage FL. A total of 35 patients with newly diagnosed FL received R-CHOP therapy with curative intent between 2002 and 2009. The median age of the 35 patients was 61 years; 7 patients had in CS 1 FL, and 28 patients, CS 2 FL. The median number of R-CHOP cycles was 6. On completion of the R-CHOP therapy, 33 patients achieved complete response and 1 showed partial response (PR). The patient showing PR after the completion of R-CHOP was administered additional irradiation. The remaining 1 patient was not evaluated because of discontinuation of hospital visit. In all the 35 patients, the 5-year PFS rate was 70%, and the 5-year overall survival rate was 92%. In the 15 patients with a PFS>5 years, only 1 patient showed disease progression. The outcome of R-CHOP therapy alone in patients with limited-stage FL was at least equivalent to the reported outcome of irradiation therapy alone. R-CHOP therapy could be an alternative to irradiation therapy in limited-stage FL patients.
authors: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan. Electronic address: cavalier@ch-yamate.dlenet.com.
authors: Naoto
authors: N
authors: Tomita
authors: Department of Hematology, Shizuoka Red Cross Hospital, Japan.
authors: Taisei
authors: T
authors: Suzuki
authors: Department of Hematology, Yokosuka City Hospital, Japan.
authors: Yasufumi
authors: Y
authors: Ishiyama
authors: Department of Hematology/Immunology, Fujisawa City Hospital, Japan.
authors: Kazuho
authors: K
authors: Miyashita
authors: Department of Medical Oncology, Kanagawa Cancer Center, Japan.
authors: Hiroyuki
authors: H
authors: Takahashi
authors: Department of Hematology, Yokohama City University Medical Center, Japan.
authors: Ayumi
authors: A
authors: Numata
authors: Department of Hematology, Shizuoka Red Cross Hospital, Japan.
authors: Satomi
authors: S
authors: Ito
authors: Department of Hematology, Yokohama City University Medical Center, Japan.
authors: Kenji
authors: K
authors: Motohashi
authors: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan.
authors: Takayoshi
authors: T
authors: Tachibana
authors: Department of Medical Oncology, Kanagawa Cancer Center, Japan.
authors: Hirotaka
authors: H
authors: Takasaki
authors: Department of Hematology/Immunology, Fujisawa City Hospital, Japan.
authors: Rika
authors: R
authors: Kawasaki
authors: Department of Hematology, Yokohama City University Medical Center, Japan.
authors: Maki
authors: M
authors: Hagihara
authors: Department of Hematology/Oncology, Yamato Municipal Hospital, Japan.
authors: Chizuko
authors: C
authors: Hashimoto
authors: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan.
authors: Etsuko
authors: E
authors: Yamazaki
authors: Department of Hematology, Shizuoka Red Cross Hospital, Japan.
authors: Jun
authors: J
authors: Taguchi
authors: Department of Hematology/Immunology, Fujisawa City Hospital, Japan.
authors: Katsumichi
authors: K
authors: Fujimaki
authors: Department of Medical Oncology, Kanagawa Cancer Center, Japan.
authors: Rika
authors: R
authors: Sakai
authors: Department of Hematology, Yokohama City University Medical Center, Japan.
authors: Shin
authors: S
authors: Fujisawa
authors: Department of Medical Oncology, Kanagawa Cancer Center, Japan.
authors: Shigeki
authors: S
authors: Motomura
authors: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan.
authors: Yoshiaki
authors: Y
authors: Ishigatsubo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Follicular lymphoma; Immunochemotherapy; Limited-stage; R-CHOP; Rituximab